Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation. Issue 9 (26th May 2013)

• Record Type: Journal Article
• Authors: Uchida, Mayako; Kato, Koji; Ikesue, Hiroaki; Ichinose, Kimiko; Hiraiwa, Hiromi; Sakurai, Asako; Muta, Tsuyoshi; Takenaka, Katsuto; Iwasaki, Hiromi; Miyamoto, Toshihiro; Teshima, Takanori; Shiratsuchi, Motoaki; Suetsugu, Kimitaka; Nagata, Kenichiro; Egashira, Nobuaki; Akashi, Koichi; Oishi, Ryozo
• Is Part Of: Pharmacotherapy. Volume 33:Issue 9(2013)
• Page Start: 893
• Page End: 901
• Publication Date: 2013-05-26
• Subjects: Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.1294
• Languages: English
• ISSNs: 0277-0008

Abstract

<abstract abstract-type="main" id="phar1294-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="phar1294-sec-0001" sec-type="section"> <title>Study Objective</title> <p>To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high‐dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo‐HSCT).</p> </sec> <sec id="phar1294-sec-0002" sec-type="section"> <title>Design</title> <p>Retrospective medical record review.</p> </sec> <sec id="phar1294-sec-0003" sec-type="section"> <title>Setting</title> <p>Hematology ward of a university hospital in Japan.</p> </sec> <sec id="phar1294-sec-0004" sec-type="section"> <title>Patients</title> <p>Of 88 patients treated with high‐dose chemotherapy followed by allo‐HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010).</p> </sec> <sec id="phar1294-sec-0005" sec-type="section"> <title>Interventions</title> <p>Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60–90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3–6 days).</p> </sec> <sec id="phar1294-sec-0006" sec-type="section"> <title>Measurements and Main Results</title> <p>The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48% vs 24%, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13–7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9% vs 25%, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft‐versus‐host‐disease (63% vs 55%, p=0.52), viral infection (74% vs 67%, p=0.49), or 1‐year overall survival (63% vs 62%, p=0.90) between the two groups.</p> </sec> <sec id="phar1294-sec-0007" sec-type="section"> <title>Conclusions</title> <p>The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation‐related toxicities in allo‐HSCT.</p> </sec> </abstract>